These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
142 related items for PubMed ID: 16985289
1. The postantifungal effect (PAFE) of itraconazole, in comparison with those of miconazole and fluconazole, on Candida Species. Uchida K, Abe S, Yamaguchi H. Microbiol Immunol; 2006; 50(9):679-85. PubMed ID: 16985289 [Abstract] [Full Text] [Related]
2. [Susceptibility to miconazole and itraconazole of Candida strains isolated from hospitalized and outpatient clinic patients]. Kurnatowska AK, Kwaśniewska J. Wiad Parazytol; 2009; 55(4):415-23. PubMed ID: 20209818 [Abstract] [Full Text] [Related]
3. Antifungal susceptibility of epigallocatechin 3-O-gallate (EGCg) on clinical isolates of pathogenic yeasts. Park BJ, Park JC, Taguchi H, Fukushima K, Hyon SH, Takatori K. Biochem Biophys Res Commun; 2006 Aug 25; 347(2):401-5. PubMed ID: 16831406 [Abstract] [Full Text] [Related]
4. Antifungal susceptibilities of Candida species isolated from the patients with vaginal candidiasis. Nagashima M, Yamagishi Y, Mikamo H. J Infect Chemother; 2016 Feb 25; 22(2):124-6. PubMed ID: 26627336 [Abstract] [Full Text] [Related]
5. Postantifungal Effect of Micafungin against the Species Complexes of Candida albicans and Candida parapsilosis. Gil-Alonso S, Jauregizar N, Eraso E, Quindós G. PLoS One; 2015 Feb 25; 10(7):e0132730. PubMed ID: 26168269 [Abstract] [Full Text] [Related]
6. Turbidometric characterization of the postantifungal effect: comparative studies with amphotericin B, 5-fluorocytosine and miconazole on Candida albicans. Scalarone GM, Mikami Y, Kurita N, Ichihara Y, Yazawa K, Miyaji M. Mycoses; 1991 Feb 25; 34(7-8):297-302. PubMed ID: 1803230 [Abstract] [Full Text] [Related]
7. [Antifungal susceptibility of Candida species isolated from patient with invasive fungal peritonitis and investigation on clinical breakpoints of itraconazole]. Yamagishi Y, Terada M, Ohki E, Mikamo H. Jpn J Antibiot; 2009 Oct 25; 62(5):415-34. PubMed ID: 20055119 [Abstract] [Full Text] [Related]
8. Post-antifungal effect of polyene, azole and DNA-analogue agents against oral Candida albicans and Candida tropicalis isolates in HIV disease. Anil S, Ellepola AN, Samaranayake LP. J Oral Pathol Med; 2001 Sep 25; 30(8):481-8. PubMed ID: 11545239 [Abstract] [Full Text] [Related]
9. Postantifungal effect and effects of sub-MIC concentrations on previously treated Candida sp. influence of growth phase. García MT, Llorente MT, Mínguez F, Prieto J. J Infect; 2002 Nov 25; 45(4):263-7. PubMed ID: 12423615 [Abstract] [Full Text] [Related]
10. In vitro synergism between berberine and miconazole against planktonic and biofilm Candida cultures. Wei GX, Xu X, Wu CD. Arch Oral Biol; 2011 Jun 25; 56(6):565-72. PubMed ID: 21272859 [Abstract] [Full Text] [Related]
11. [Analysis of resistance and sensitivity of 1 200 strains of vulvovaginal candidiasis in China to five common antifungal drugs]. Fan LY, Liu ZH, Bai XN, Zong X. Zhonghua Fu Chan Ke Za Zhi; 2022 Aug 25; 57(8):601-607. PubMed ID: 36008287 [Abstract] [Full Text] [Related]
12. Influence of pH and concentration on the postantifungal effect and on the effects of sub-MIC concentrations of 4 antifungal agents on previously treated Candida spp. García MT, Llorente MT, Mínguez F, Prieto J. Scand J Infect Dis; 2000 Aug 25; 32(6):669-73. PubMed ID: 11200379 [Abstract] [Full Text] [Related]
13. The postantifungal effect (PAFE) of antimycotics on oral C. albicans isolates and its impact on candidal adhesion. Ellepola AN, Samaranayake LP. Oral Dis; 1998 Dec 25; 4(4):260-7. PubMed ID: 10200705 [Abstract] [Full Text] [Related]
14. Postantifungal effect of anidulafungin against Candida albicans, Candida dubliniensis, Candida africana, Candida parapsilosis, Candida metapsilosis and Candida orthopsilosis. Gil-Alonso S, Quindós G, Eraso E, Jauregizar N. Rev Esp Quimioter; 2019 Apr 25; 32(2):183-188. PubMed ID: 30847462 [Abstract] [Full Text] [Related]
15. [In vitro effect of itraconazole against various species of Candida]. Bastide M, Mallie M, Jouvert S, Montes B, Bastide JM. Pathol Biol (Paris); 1989 Jun 25; 37(5 Pt 2):694-9. PubMed ID: 2552381 [Abstract] [Full Text] [Related]
16. Comparison of the clinical risk factors between Candida albicans and Candida non-albicans species for bloodstream infection. Shigemura K, Osawa K, Jikimoto T, Yoshida H, Hayama B, Ohji G, Iwata K, Fujisawa M, Arakawa S. J Antibiot (Tokyo); 2014 Apr 25; 67(4):311-4. PubMed ID: 24424346 [Abstract] [Full Text] [Related]
17. In vitro susceptibility of oral Candida to seven antifungal agents. Kuriyama T, Williams DW, Bagg J, Coulter WA, Ready D, Lewis MA. Oral Microbiol Immunol; 2005 Dec 25; 20(6):349-53. PubMed ID: 16238594 [Abstract] [Full Text] [Related]
18. The in vitro post-antifungal effect of nystatin on Candida species of oral origin. Ellepola AN, Samaranayake LP. J Oral Pathol Med; 1999 Mar 25; 28(3):112-6. PubMed ID: 10069538 [Abstract] [Full Text] [Related]
19. In vitro comparative evaluations of the postantifungal effect: synergistic interaction between flucytosine and fluconazole against Candida albicans. Scalarone GM, Mikami Y, Kurita N, Yazawa K, Uno J, Miyaji M. Mycoses; 1991 Mar 25; 34(9-10):405-10. PubMed ID: 1820519 [Abstract] [Full Text] [Related]
20. [Antifungal susceptibility of Candida species causing candidemia in Kurume University Hospital and Shaiseikai Hutukaichi Hospital]. Rikimaru T, Yonemitu J, Shimada A, Koga A, Nishiyama M, Hashimoto K, Tanamachi C, Fujimoto K, Sagawa K, Aizawa H. Kansenshogaku Zasshi; 2005 Jan 25; 79(1):20-4. PubMed ID: 15717479 [Abstract] [Full Text] [Related] Page: [Next] [New Search]